Adebrelimab plus chemotherapy for advanced pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a combination of a targeted immune therapy (Adebrelimab) with three chemotherapy drugs for people with metastatic pancreatic cancer who haven't had any treatment yet. The goal is to see if this combination can shrink tumors and help people live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with metastatic pancreatic cancer (cancer that has spread to other parts of the body).
- You have not received any previous treatment for your cancer, such as chemotherapy, targeted therapy, or immunotherapy.
- You have at least one tumor that can be measured on a scan, and it has not been treated with radiation.
- Your overall health is good (ECOG score of 0 or 1), meaning you are fully active or able to do light work.
- Your major organs (like bone marrow, liver, and kidneys) are working well based on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three chemotherapy drugs (mFOLFIRINOX) along with anlotinib (a targeted therapy) and sintilimab (an immunotherapy) for people with advanced pancreatic cancer who have not had prior treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests a combination of two chemotherapy drugs (AG) plus an immunotherapy (cadonilimab) and a short course of radiation for people with locally advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this approach helps shrink or control the tumor.
This trial tests a combination of an immunotherapy drug (adebrelimab) with two chemotherapy drugs (gemcitabine and nab-paclitaxel) for people with advanced pancreatic cancer that has progressed after prior treatment. The goal is to see if adding immunotherapy can help shrink tumors or slow the cancer down.
This trial tests a new immunotherapy drug (adebrelimab) combined with a standard chemotherapy cocktail (NALIRIFOX) for people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination shrinks or controls the cancer better than chemo alone.
This trial tests adding the immunotherapy drug adebrelimab to standard chemotherapy before surgery for pancreatic cancer that can be removed. The goal is to see if this combination shrinks tumors more effectively.
This trial tests a combination of two drugs (Adebrelimab and Chidamide) in people with advanced pancreatic cancer that cannot be removed by surgery or has spread to other parts of the body. The goal is to see if this treatment can help shrink tumors or slow the cancer's growth.
Hear when a new Adebrelimab (SHR-1316) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.